BLAINJECTIONINJECTABLE
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
5/8 — Partial
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVENITY (romosozumab-aqqg) is a monoclonal antibody (mAb) approved by FDA in April 2019 for the treatment of osteoporosis in postmenopausal women at high risk of fracture. It works by inhibiting sclerostin, a protein that suppresses bone formation, thereby increasing bone mineral density and reducing fracture risk. The drug is administered as a subcutaneous injection.
$0.001BPart D
PeakProduct is at peak commercial stage with modest Part D penetration (440 claims in 2023), suggesting opportunity for brand expansion teams focused on market penetration and physician engagement.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections
Started Sep 2026
308 enrolled
Healthy Participants
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
Started Mar 2026
71 enrolled
Osteogenesis Imperfecta
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
Started Apr 2024
111 enrolled
Osteogenesis Imperfecta
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
Started Oct 2023
100 enrolled
Postmenopausal Osteoporosis
Romosozumab in Women With Chronic SCI
Started Mar 2021
12 enrolled
OsteoporosisBone LossOsteopenia, Osteoporosis+2 more
Worked on EVENITY at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.